Statements of Income
Performance by Subgroup and Segment
Bayer Links
Management Report
Bayer HealthCare
Sales of the HealthCare subgroup rose in the second quarter of 2007 by 64.7 percent to €3,717 million (Q2 2006: €2,257 million), with the acquired business of Schering, Berlin, Germany, accounting for €1,489 million (Q2 2006: €144 million pro rata temporis). Adjusted for currency and portfolio effects, sales increased by 9.3 percent thanks to the positive business trend in both segments.
Bayer HealthCare improved EBITDA before special items by 106.2 percent in the second quarter of 2007, to €969 million (Q2 2006: €470 million). The increase was mainly due to the earnings contributions from the acquired Schering business and the synergies of around €100 million already realized. EBIT before special items also came in considerably above the prior-year period, at €640 million (Q2 2006: €371 million). After special charges of €209 million related to the integration of Schering, EBIT amounted to €431 million, which was 21.4 percent more than for the same period of last year.
Bayer HealthCare improved EBITDA before special items by 106.2 percent in the second quarter of 2007, to €969 million (Q2 2006: €470 million). The increase was mainly due to the earnings contributions from the acquired Schering business and the synergies of around €100 million already realized. EBIT before special items also came in considerably above the prior-year period, at €640 million (Q2 2006: €371 million). After special charges of €209 million related to the integration of Schering, EBIT amounted to €431 million, which was 21.4 percent more than for the same period of last year.
| Bayer HealthCare | 2nd Quarter 2006 | 2nd Quarter 2007 | Change | 1st Half 2006 | 1st Half 2007 | Change |
| € million | € million | % | € million | € million | % | |
| Net sales | 2,257 | 3,717 | +64.7 | 4,460 | 7,327 | +64.3 |
| EBITDA1 | 454 | 788 | +73.6 | 913 | 1,571 | +72.1 |
| Special items | (16) | (181) | (22) | (346) | ||
| EBITDA before special items2 | 470 | 969 | +106.2 | 935 | 1,917 | +105.0 |
| EBITDA margin before special items | 20.8% | 26.1% | 21.0% | 26.2% | ||
| EBIT1 | 355 | 431 | +21.4 | 734 | 916 | +24.8 |
| Special items | (16) | (209) | (22) | (348) | ||
| EBIT before special items2 | 371 | 640 | +72.5 | 756 | 1,264 | +67.2 |
| Gross cash flow1 | 336 | 545 | +62.2 | 628 | 1,102 | +75.5 |
| Net cash flow1 | 367 | 284 | -22.6 | 410 | 667 | +62.7 |
1 for definition see Bayer Group Key Data
2 for definition see also Calculation of EBIT(DA) Before Special Items
2 for definition see also Calculation of EBIT(DA) Before Special Items
| Pharmaceuticals | 2nd Quarter 2006 | 2nd Quarter 2007 | Change | 1st Half 2006 | 1st Half 2007 | Change |
| € million | € million | % | € million | € million | % | |
| Sales | 1,188 | 2,583 | +117.4 | 2,336 | 5,078 | +117.4 |
| Primary Care1 | 753 | 766 | +1.7 | 1,540 | 1,539 | -0.1 |
| Women’s Healthcare2 | 58 | 652 | • | 58 | 1,279 | • |
| Diagnostic Imaging (including Medrad)2 | 37 | 330 | • | 37 | 637 | • |
| Specialized Therapeutics2 | 30 | 310 | • | 30 | 613 | • |
| Hematology/Cardiology | 252 | 271 | +7.5 | 579 | 539 | -6.9 |
| Oncology3 | 52 | 188 | • | 86 | 347 | • |
| Dermatology (Intendis)2 | 6 | 66 | • | 6 | 124 | • |
| EBITDA4 | 223 | 530 | +137.7 | 464 | 1,076 | +131.9 |
| Special items | (14) | (181) | (19) | (346) | ||
| EBITDA before special items5 | 237 | 711 | • | 483 | 1,422 | +194.4 |
| EBITDA margin before special items | 19.9% | 27.5% | 20.7% | 28.0% | ||
| EBIT4 | 159 | 207 | +30.2 | 361 | 488 | +35.2 |
| Special items | (14) | (209) | (19) | (348) | ||
| EBIT before special items5 | 173 | 416 | +140.5 | 380 | 836 | +120.0 |
| Gross cash flow4 | 157 | 381 | +142.7 | 319 | 771 | +141.7 |
| Net cash flow4 | 284 | 202 | -28.9 | 273 | 481 | +76.2 |
2006 figures restated
1 Schering andrology business included in 2006 pro rata temporis
2 Schering sales included in 2006 pro rata temporis
3 Schering oncology business included in 2006 pro rata temporis
4 for definition see Bayer Group Key Data
5 for definition see also Calculation of EBIT(DA) Before Special Items
1 Schering andrology business included in 2006 pro rata temporis
2 Schering sales included in 2006 pro rata temporis
3 Schering oncology business included in 2006 pro rata temporis
4 for definition see Bayer Group Key Data
5 for definition see also Calculation of EBIT(DA) Before Special Items
Pharmaceuticals
Sales of our Pharmaceuticals segment rose by €1,395 million in the second quarter of 2007, to €2,583 million (Q2 2006: €1,188 million), with the acquired business of Schering, Berlin, Germany, accounting for €1,489 million (Q2 2006: €144 million pro rata temporis). Adjusted for currency and portfolio changes, we experienced growth of 9.0 percent, due primarily to sharply higher sales of Nexavar® and Kogenate®.
The figures for the second quarter of 2006 include the business of Schering, Berlin, Germany for the period June 23 through June 30, 2006. The commentaries given below on business developments related to the acquired products include comparisons with data for the second quarter of 2006 that were prepared by Schering AG, Berlin, Germany, and do not form part of the consolidated interim financial statements of the Bayer Group. We refer to those figures as “pro forma.”
The figures for the second quarter of 2006 include the business of Schering, Berlin, Germany for the period June 23 through June 30, 2006. The commentaries given below on business developments related to the acquired products include comparisons with data for the second quarter of 2006 that were prepared by Schering AG, Berlin, Germany, and do not form part of the consolidated interim financial statements of the Bayer Group. We refer to those figures as “pro forma.”
| Best-Selling Pharmaceutical Products | 2nd Quarter 2006 | 2nd Quarter 2007 | Change | Currency- adjusted change | 1st Half 2006 | 1st Half 2007 | Change | Currency- adjusted change |
| € million | € million | % | % | € million | € million | % | % | |
| Betaferon®/Betaseron® * (Specialized Therapeutics) | 25 | 256 | • | • | 25 | 500 | • | • |
| Yasmin®/YAZ®/ Yasminelle® * (Women’s Healthcare) | 17 | 250 | • | • | 17 | 490 | • | • |
| Kogenate® (Hematology/Cardiology) | 179 | 210 | +17.3 | +20.1 | 383 | 411 | +7.3 | +11.1 |
| Adalat® (Primary Care) | 171 | 162 | -5.3 | +0.5 | 328 | 307 | -6.4 | -0.1 |
| Avalox®/Avelox® (Primary Care) | 88 | 90 | +2.3 | +4.0 | 218 | 218 | 0.0 | +3.9 |
| Cipro®/Ciprobay® (Primary Care) | 127 | 93 | -26.8 | -24.3 | 259 | 201 | -22.4 | -19.6 |
| Mirena® * (Women’s Healthcare) | 8 | 88 | • | • | 8 | 169 | • | • |
| Levitra® (Primary Care) | 73 | 81 | +11.0 | +15.0 | 151 | 165 | +9.3 | +14.8 |
| Magnevist® * (Diagnostic Imaging) | 9 | 74 | • | • | 9 | 154 | • | • |
| Glucobay® (Primary Care) | 76 | 79 | +3.9 | +7.8 | 153 | 151 | -1.3 | +3.2 |
| Ultravist® * (Diagnostic Imaging) | 7 | 64 | • | • | 7 | 119 | • | • |
| CardioAspirin® (Primary Care) | 53 | 57 | +7.5 | +12.4 | 101 | 111 | +9.9 | +14.1 |
| Nexavar® (Oncology) | 23 | 60 | +160.9 | +167.6 | 43 | 107 | +148.8 | +157.5 |
| Iopamiron® * (Diagnostic Imaging) | 6 | 57 | • | • | 6 | 104 | • | • |
| Diane® * (Women’s Healthcare) | 5 | 43 | • | • | 5 | 88 | • | • |
| Total | 867 | 1,664 | • | • | 1,713 | 3,295 | • | • |
| Proportion of Pharmaceuticals sales | 73% | 64% | 73% | 65% |
Products ranked by first-half 2007 sales
* acquired Schering product, sales included in 2006 pro rata temporis
* acquired Schering product, sales included in 2006 pro rata temporis
| Best-Selling Schering Products (pro forma) | 2nd Quarter 2006 | 2nd Quarter 2007 | Change | Currency- adjusted change | 1st Half 2006 | 1st Half 2007 | Change | Currency- adjusted change |
| € million | € million | % | % | € million | € million | % | % | |
| Betaferon®/Betaseron® (Specialized Therapeutics) | 249 | 256 | +2.8 | +5.6 | 481 | 500 | +4.0 | +7.7 |
| Yasmin®/YAZ®/ Yasminelle® (Women’s Healthcare) | 181 | 250 | +38.1 | +43.1 | 361 | 490 | +35.7 | +42.1 |
| Mirena® (Women’s Healthcare) | 75 | 88 | +17.3 | +21.3 | 143 | 169 | +18.2 | +23.1 |
| Magnevist® (Diagnostic Imaging) | 85 | 74 | -12.9 | -9.4 | 161 | 154 | -4.3 | +0.6 |
| Ultravist® (Diagnostic Imaging) | 71 | 64 | -9.9 | -9.9 | 143 | 119 | -16.8 | -15.4 |
| Iopamiron® (Diagnostic Imaging) | 62 | 57 | -8.1 | 0.0 | 110 | 104 | -5.5 | +3.6 |
| Diane® (Women’s Healthcare) | 45 | 43 | -4.4 | -2.2 | 92 | 88 | -4.3 | -2.2 |
Sales of the Primary Care business unit in the second quarter of 2007 came to €766 million (Q2 2006: €753 million). Adjusted for currency and portfolio effects, the increase was 3.5 percent. The main growth driver was Levitra®, with currency-adjusted sales up 15.0 percent, while increasing competition from generic products led to a marked decline for Cipro®/Ciprobay®, sales of which fell 24.3 percent on a currency-adjusted basis. This effect was partially offset by sales in Japan of the novel cholesterol-lowering drug ZETIA®. We have comarketing rights for this Schering-Plough product in Japan, where it received marketing approval in April 2007. (Please note that Schering-Plough Corporation, New Jersey, and the company acquired by Bayer in June 2006, i.e. Bayer Schering Pharma AG (formerly named Schering AG), Berlin, Germany, are unaffiliated companies that have been totally independent of each other for many years.)
In our Women’s Healthcare business unit, we achieved sales of €652 million in the second quarter of 2007 (Q2 2006: €58 million pro rata temporis). Principal growth drivers here were the oral contraceptives of the Yasmin®/YAZ®/Yasminelle® product line, sales of which rose by 43.1 percent (pro forma) in the second quarter when adjusted for currency changes. This positive performance was due particularly to the launches of Yasminelle® in Europe and YAZ® in the United States and Latin America. Business with our intra-uterine system Mirena® also made encouraging progress in the second quarter, advancing by 21.3 percent (pro forma) on a currency-adjusted basis. Growth was due mainly to increased sales in the United States.
Sales of the Diagnostic Imaging business unit in the second quarter of 2007 came to €330 million (Q2 2006: €37 million pro rata temporis). While the Medrad business expanded by 11.6 percent (pro forma) when adjusted for currency changes, Magnevist® and Ultravist® showed currency-adjusted, pro forma declines of 9.4 and 9.9 percent, respectively. Having voluntarily withdrawn the 370 mgI/ml formulation of Ultravist® in the summer of 2006, we have resumed sales of this product in most countries since the first quarter of 2007. Its relaunch in the U.S. market is scheduled for August 2007.
Sales of the Specialized Therapeutics business unit in the second quarter of 2007 amounted to €310 million (Q2 2006: €30 million pro rata temporis). Currency-adjusted sales of our top product Betaferon®/Betaseron® to treat multiple sclerosis (MS) advanced by 5.6 percent (pro forma).
Sales of the Hematology/Cardiology business unit rose by €19 million in the second quarter of 2007, to €271 million (Q2 2006: €252 million). This represents an increase of 17.6 percent after adjusting for currency and portfolio effects. Second-quarter currency-adjusted sales of Kogenate® advanced by 20.1 percent because part of the sales volume expected for the first quarter was delayed until the second quarter. However, currency-adjusted sales of Trasylol®, our product for use during open-heart surgery, declined by 18.4 percent. Two separate observational studies reported on a possible correlation between the administration of Trasylol® (aprotinin) and severe renal dysfunction and vasoconstriction (myocardial infarction and stroke). A follow-up study to one of them reported on a possible correlation between administration of this product and increased long-term mortality. Based on our study data and many years of experience with Trasylol®, Bayer believes that this product is a safe and effective medicine when used correctly. We are currently cooperating closely with the relevant regulatory authorities to resolve the questions that have arisen. In this connection a joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled for September 12, 2007.
Our Oncology business unit lifted sales substantially in the second quarter, to €188 million (Q2 2006: €52 million). Included in this figure is €113 million in sales of the acquired oncology business of Schering AG, Berlin, Germany, which mainly comprises the key products Fludara® and Campath®. Currency- and portfolio-adjusted sales rose by 75.4 percent. This was mainly due to the very successful development of Nexavar®, sales of which rose to €60 million (Q2 2006: €23 million).
The Dermatology (Intendis) business unit achieved sales of €66 million in the second quarter of 2007. The main sales drivers were the principal products Skinoren® and Advantan®, sales of which rose by 13.4 percent and 9.6 percent (pro forma), respectively, after adjusting for currency changes.
EBITDA before special items for the Pharmaceuticals segment moved ahead in the second quarter of 2007 to €711 million (Q2 2006: €237 million). As in the preceding quarter, the substantial increase was largely due to the earnings contributions from the acquired Schering business and the synergies already achieved. EBIT before special items came in €243 million, or 140.5 percent, above the prior-year quarter, at €416 million. After special charges of €209 million related to the acquisition and integration of Schering, Berlin, Germany, EBIT advanced by €48 million, or 30.2 percent, to €207 million.
First-half sales of the Pharmaceuticals segment increased to €5,078 million (Q2 2006: €2,336 million), including a €2,899 million contribution (Q2 2006: €144 million pro rata temporis) from the acquired Schering business. This is equivalent to a 6.7 percent increase after adjusting for currency and portfolio changes. Contributing especially to this growth were the gratifying gains by our core products Nexavar®, Levitra® and Kogenate®, which compensated for the expected drop in sales of Cipro®/Ciprobay®. The Pharmaceuticals segment saw EBITDA before special items for the first half of 2007 advance to €1,422 million (H1 2006: €483 million). EBIT before special items climbed by €456 million, or 120 percent, to €836 million. After special charges of €348 million, EBIT rose by €127 million, or 35.2 percent, to €488 million.
To safeguard our Betaseron® business, we signed an agreement with Novartis in the first quarter of 2007 to acquire the biologics manufacturing facility in Emeryville, California. Bayer Schering Pharma will continue to pay Novartis royalties equivalent to those being paid currently on net sales of Betaseron® manufactured by Bayer at the Emeryville facilities until the original agreement with Novartis expires in October 2008. After this date, no more royalties will be due to Novartis on the sales of Betaseron®. Bayer Schering Pharma will also acquire the existing inventories. In return, Novartis will receive a license to establish its own brand based on interferon beta-1b starting in 2009. When it is approved by the regulatory authorities, Bayer Schering Pharma will manufacture the product for Novartis from 2009 forward and receive in return a royalty from Novartis.
In our Women’s Healthcare business unit, we achieved sales of €652 million in the second quarter of 2007 (Q2 2006: €58 million pro rata temporis). Principal growth drivers here were the oral contraceptives of the Yasmin®/YAZ®/Yasminelle® product line, sales of which rose by 43.1 percent (pro forma) in the second quarter when adjusted for currency changes. This positive performance was due particularly to the launches of Yasminelle® in Europe and YAZ® in the United States and Latin America. Business with our intra-uterine system Mirena® also made encouraging progress in the second quarter, advancing by 21.3 percent (pro forma) on a currency-adjusted basis. Growth was due mainly to increased sales in the United States.
Sales of the Diagnostic Imaging business unit in the second quarter of 2007 came to €330 million (Q2 2006: €37 million pro rata temporis). While the Medrad business expanded by 11.6 percent (pro forma) when adjusted for currency changes, Magnevist® and Ultravist® showed currency-adjusted, pro forma declines of 9.4 and 9.9 percent, respectively. Having voluntarily withdrawn the 370 mgI/ml formulation of Ultravist® in the summer of 2006, we have resumed sales of this product in most countries since the first quarter of 2007. Its relaunch in the U.S. market is scheduled for August 2007.
Sales of the Specialized Therapeutics business unit in the second quarter of 2007 amounted to €310 million (Q2 2006: €30 million pro rata temporis). Currency-adjusted sales of our top product Betaferon®/Betaseron® to treat multiple sclerosis (MS) advanced by 5.6 percent (pro forma).
Sales of the Hematology/Cardiology business unit rose by €19 million in the second quarter of 2007, to €271 million (Q2 2006: €252 million). This represents an increase of 17.6 percent after adjusting for currency and portfolio effects. Second-quarter currency-adjusted sales of Kogenate® advanced by 20.1 percent because part of the sales volume expected for the first quarter was delayed until the second quarter. However, currency-adjusted sales of Trasylol®, our product for use during open-heart surgery, declined by 18.4 percent. Two separate observational studies reported on a possible correlation between the administration of Trasylol® (aprotinin) and severe renal dysfunction and vasoconstriction (myocardial infarction and stroke). A follow-up study to one of them reported on a possible correlation between administration of this product and increased long-term mortality. Based on our study data and many years of experience with Trasylol®, Bayer believes that this product is a safe and effective medicine when used correctly. We are currently cooperating closely with the relevant regulatory authorities to resolve the questions that have arisen. In this connection a joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled for September 12, 2007.
Our Oncology business unit lifted sales substantially in the second quarter, to €188 million (Q2 2006: €52 million). Included in this figure is €113 million in sales of the acquired oncology business of Schering AG, Berlin, Germany, which mainly comprises the key products Fludara® and Campath®. Currency- and portfolio-adjusted sales rose by 75.4 percent. This was mainly due to the very successful development of Nexavar®, sales of which rose to €60 million (Q2 2006: €23 million).
The Dermatology (Intendis) business unit achieved sales of €66 million in the second quarter of 2007. The main sales drivers were the principal products Skinoren® and Advantan®, sales of which rose by 13.4 percent and 9.6 percent (pro forma), respectively, after adjusting for currency changes.
EBITDA before special items for the Pharmaceuticals segment moved ahead in the second quarter of 2007 to €711 million (Q2 2006: €237 million). As in the preceding quarter, the substantial increase was largely due to the earnings contributions from the acquired Schering business and the synergies already achieved. EBIT before special items came in €243 million, or 140.5 percent, above the prior-year quarter, at €416 million. After special charges of €209 million related to the acquisition and integration of Schering, Berlin, Germany, EBIT advanced by €48 million, or 30.2 percent, to €207 million.
First-half sales of the Pharmaceuticals segment increased to €5,078 million (Q2 2006: €2,336 million), including a €2,899 million contribution (Q2 2006: €144 million pro rata temporis) from the acquired Schering business. This is equivalent to a 6.7 percent increase after adjusting for currency and portfolio changes. Contributing especially to this growth were the gratifying gains by our core products Nexavar®, Levitra® and Kogenate®, which compensated for the expected drop in sales of Cipro®/Ciprobay®. The Pharmaceuticals segment saw EBITDA before special items for the first half of 2007 advance to €1,422 million (H1 2006: €483 million). EBIT before special items climbed by €456 million, or 120 percent, to €836 million. After special charges of €348 million, EBIT rose by €127 million, or 35.2 percent, to €488 million.
To safeguard our Betaseron® business, we signed an agreement with Novartis in the first quarter of 2007 to acquire the biologics manufacturing facility in Emeryville, California. Bayer Schering Pharma will continue to pay Novartis royalties equivalent to those being paid currently on net sales of Betaseron® manufactured by Bayer at the Emeryville facilities until the original agreement with Novartis expires in October 2008. After this date, no more royalties will be due to Novartis on the sales of Betaseron®. Bayer Schering Pharma will also acquire the existing inventories. In return, Novartis will receive a license to establish its own brand based on interferon beta-1b starting in 2009. When it is approved by the regulatory authorities, Bayer Schering Pharma will manufacture the product for Novartis from 2009 forward and receive in return a royalty from Novartis.
Consumer Health
Sales of our Consumer Health segment in the second quarter of 2007 were €1,134 million (Q2 2006: €1,069 million). On a currency- and portfolio-adjusted basis this corresponds to a 9.6 percent increase, which was well ahead of market growth and to which all divisions contributed.
The Consumer Care Division posted second-quarter sales of €624 million (Q2 2006: €604 million). Adjusted for currency effects, sales rose by 6.3 percent. Among our top products, Bepanthen®/Bepanthol® (+17.6 percent, currency-adjusted) and Canesten® (+18.6 percent, currency-adjusted) performed very well.
Sales of the Diabetes Care Division showed a particularly strong gain, to €244 million (Q2 2006: €213 million). On a currency-adjusted basis the increase came to 19.7 percent. This pleasing trend was mainly due to the successful marketing of our blood glucose monitoring systems Ascensia® Contour® and Ascensia® Breeze®, which replace the older Elite® systems in the Ascensia® product family.
Second-quarter sales of the Animal Health Division rose to €266 million (Q2 2006: €252 million), with currency-adjusted sales growth amounting to 9.6 percent. Contributing particularly to the increase was the Advantage® product line, which saw business expand by 20.1 percent.
EBITDA before special items for the Consumer Health segment advanced in the second quarter of 2007 by 10.7 percent to €258 million (Q2 2006: €233 million). Earnings on the additional business more than offset the higher marketing expenses necessary to support product introductions planned for 2007. EBIT before special items moved ahead 13.1 percent to €224 million (Q2 2006: €198 million). EBIT amounted to €224 million (Q2 2006: €196 million).
Sales of the Consumer Health segment in the first half of 2007 increased by €125 million to €2,249 million. Adjusted for currency effects, the increase came to 10.6 percent. The Consumer Health segment posted a €43 million increase in first-half EBITDA before special items, to €495 million. EBIT before special items rose by 13.8 percent to €428 million (H1 2006: €376 million). EBIT amounted to €428 million (H1 2006: €373 million).
The Consumer Care Division posted second-quarter sales of €624 million (Q2 2006: €604 million). Adjusted for currency effects, sales rose by 6.3 percent. Among our top products, Bepanthen®/Bepanthol® (+17.6 percent, currency-adjusted) and Canesten® (+18.6 percent, currency-adjusted) performed very well.
Sales of the Diabetes Care Division showed a particularly strong gain, to €244 million (Q2 2006: €213 million). On a currency-adjusted basis the increase came to 19.7 percent. This pleasing trend was mainly due to the successful marketing of our blood glucose monitoring systems Ascensia® Contour® and Ascensia® Breeze®, which replace the older Elite® systems in the Ascensia® product family.
Second-quarter sales of the Animal Health Division rose to €266 million (Q2 2006: €252 million), with currency-adjusted sales growth amounting to 9.6 percent. Contributing particularly to the increase was the Advantage® product line, which saw business expand by 20.1 percent.
EBITDA before special items for the Consumer Health segment advanced in the second quarter of 2007 by 10.7 percent to €258 million (Q2 2006: €233 million). Earnings on the additional business more than offset the higher marketing expenses necessary to support product introductions planned for 2007. EBIT before special items moved ahead 13.1 percent to €224 million (Q2 2006: €198 million). EBIT amounted to €224 million (Q2 2006: €196 million).
Sales of the Consumer Health segment in the first half of 2007 increased by €125 million to €2,249 million. Adjusted for currency effects, the increase came to 10.6 percent. The Consumer Health segment posted a €43 million increase in first-half EBITDA before special items, to €495 million. EBIT before special items rose by 13.8 percent to €428 million (H1 2006: €376 million). EBIT amounted to €428 million (H1 2006: €373 million).
| Consumer Health | 2nd Quarter 2006 | 2nd Quarter 2007 | Change | 1st Half 2006 | 1st Half 2007 | Change |
| € million | € million | % | € million | € million | % | |
| Net sales | 1,069 | 1,134 | +6.1 | 2,124 | 2,249 | +5.9 |
| Consumer Care | 604 | 624 | +3.3 | 1,246 | 1,283 | +3.0 |
| Diabetes Care | 213 | 244 | +14.6 | 406 | 470 | +15.8 |
| Animal Health | 252 | 266 | +5.6 | 472 | 496 | +5.1 |
| EBITDA1 | 231 | 258 | +11.7 | 449 | 495 | +10.2 |
| Special items | (2) | 0 | (3) | 0 | ||
| EBITDA before special items2 | 233 | 258 | +10.7 | 452 | 495 | +9.5 |
| EBITDA margin before special items | 21.8% | 22.8% | 21.3% | 22.0% | ||
| EBIT1 | 196 | 224 | +14.3 | 373 | 428 | +14.7 |
| Special items | (2) | 0 | (3) | 0 | ||
| EBIT before special items2 | 198 | 224 | +13.1 | 376 | 428 | +13.8 |
| Gross cash flow1 | 179 | 164 | -8.4 | 309 | 331 | +7.1 |
| Net cash flow1 | 83 | 82 | -1.2 | 137 | 186 | +35.8 |
1 for definition see Bayer Group Key Data
2 for definition see also Calculation of EBIT(DA) Before Special Items
2 for definition see also Calculation of EBIT(DA) Before Special Items
| Best-Selling Consumer Health Products | 2nd Quarter 2006 | 2nd Quarter 2007 | Change | Currency- adjusted change | 1st Half 2006 | 1st Half 2007 | Change | Currency- adjusted change |
| million € | million € | % | % | million € | million € | % | % | |
| Ascensia® product line (Diabetes Care) | 208 | 241 | +15.9 | +20.2 | 398 | 464 | +16.6 | +21.9 |
| Aspirin®* (Consumer Care) | 115 | 107 | -7.0 | -3.8 | 231 | 220 | -4.8 | -0.7 |
| Advantage® product line (Animal Health) | 91 | 105 | +15.4 | +20.1 | 150 | 180 | +20.0 | +26.1 |
| Aleve®/naproxen (Consumer Care) | 56 | 55 | -1.8 | +3.6 | 109 | 124 | +13.8 | +21.8 |
| Canesten® (Consumer Care) | 40 | 47 | +17.5 | +18.6 | 81 | 90 | +11.1 | +12.9 |
| Bepanthen®/ Bepanthol® (Consumer Care) | 34 | 40 | +17.6 | +17.6 | 69 | 76 | +10.1 | +11.2 |
| Baytril® (Animal Health) | 35 | 33 | -5.7 | -1.0 | 75 | 73 | -2.7 | +1.1 |
| Supradyn® (Consumer Care) | 31 | 32 | +3.2 | +7.5 | 66 | 65 | -1.5 | +1.8 |
| One-A-Day® (Consumer Care) | 30 | 29 | -3.3 | +4.3 | 60 | 60 | 0.0 | +8.2 |
| Rennie® (Consumer Care) | 23 | 25 | +8.7 | +8.5 | 49 | 52 | +6.1 | +6.9 |
| Total | 663 | 714 | +7.7 | +11.6 | 1,288 | 1,404 | +9.0 | +13.8 |
| Proportion of Consumer Health sales | 62% | 63% | 61% | 62% |
* Total Aspirin® second-quarter sales = €164 million (Q2 2006: €168 million), first-half sales = €331 million (H1 2006: €332 million) including Aspirin® Cardio, which is reflected in sales of the Pharmaceuticals segment
Bookmark this page
E-mail this page
Advanced Search
